Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.

about

Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.

Item

http://www.wikidata.org/entity/Q36235571

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.

@ast

Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.

@en

type

Item

label

Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.

@ast

Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.

@en

prefLabel

Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.

@ast

Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.

@en

P1476

Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy

@en

P2093

Markus F Neurath

http://www.w3.org/2001/XMLSchema#string

Massimo C Fantini

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

P304

681-694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.5.4.681

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christoph Becker

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16111468

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer